Furiex Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1998-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://furiex.com
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 1282
- Registration Number
- NCT01553591
- Locations
- 🇬🇧
Furiex Research Site, Torpoint, United Kingdom
🇺🇸Furix Research Site, Hialeah, Florida, United States
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 1146
- Registration Number
- NCT01553747
- Locations
- 🇬🇧
Furiex Research Site, Wigan, United Kingdom
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
Phase 2
Completed
- Conditions
- MyalgiaHypercholesterolemiaHyperlipidemia
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 282
- Registration Number
- NCT01279590
- Locations
- 🇺🇸
Furiex research site, Richmond, Virginia, United States
🇺🇸Furiex, Spokane, Washington, United States
🇺🇸Furiex Research site, Boise, Idaho, United States
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
Phase 2
Terminated
- Conditions
- Community-Acquired Bacterial Pneumonia (CABP)
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT01198626
- Locations
- 🇵🇱
Furiex Research Site, Warszawa, Poland
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 807
- Registration Number
- NCT01130272
- Locations
- 🇺🇸
Furiex Research Site, Milwaukee, Wisconsin, United States
Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)
Phase 2
Completed
- Conditions
- Complicated Skin and Skin Structure Infections
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2011-12-16
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 161
- Registration Number
- NCT01128530
- Locations
- 🇺🇸
Furiex Research Site, Webster, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath